Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921...
Biomed Industries, Inc. (“BIOMED” or the “Company”) announced that it has entered into a definitive share exchange agreement on September 16, 2022 with MedAware...